{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:52:55Z","timestamp":1788817975548,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Radiumhemmet Research Fund"},{"name":"Cronqvist Foundation"},{"DOI":"10.13039\/100016290","name":"Cancer- and Allergy Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016290","id-type":"DOI","asserted-by":"crossref"}]},{"name":"John and Inga Hain Foundation"},{"name":"WelanderFinsen Foundation"},{"DOI":"10.13039\/100016409","name":"Gyllenstiernska Krapperup foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Melanoma-specific survival (MSS) is heterogenous between stages and is highly dependent on the T stage for primary localized disease. New systemic therapies for metastatic cutaneous melanoma (CM) have been introduced since 2012 in Sweden.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To analyse the incidence and MSS time trends between 1990 and 2020 in Sweden.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Nationwide, population-based and prospectively collected clinico-pathological data on invasive CM from the Swedish Melanoma Registry (SweMR) were analysed for survival trends between 1990 and 2020 using Kaplan\u2013Meier curves and Cox proportional hazard ratios (HRs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 77 036 primary invasive CMs were diagnosed in 70 511 patients in Sweden between 1990 and 2020. The 5-year MSS [95% confidence interval (CI)] was 88.9% (88.3\u201389.4) for 1990\u20132000, 89.2% (88.7\u201389.6) for 2001\u20132010 and 93.0% (92.7\u201393.9) for 2011\u20132020. The odds ratios for being diagnosed with nodular melanoma (vs. superficial spreading melanoma) was significantly reduced by 20% (2001\u20132010) and by 46% (2011\u20132020)\u00a0vs. the reference period 1990\u20132000. Overall, the MSS improved over both diagnostic periods (2001\u20132010 and 2011\u20132020) vs. the reference period 1990\u20132000 among men and women, respectively [HRmen: 2001\u20132010: 0.89 (95% CI 0.82\u20130.96) and 2011\u20132020: 0.62 (95% CI 0.56\u20130.67); HRwomen: 2001\u20132010: 0.82 (95% CI 0.74\u20130.91) and 2011\u20132020: 0.62 (95% CI 0.56\u20130.70)]. The risk of death from CM was significantly lower in all age groups for both men and women in the most recent diagnostic period (2011\u20132020 vs.1990\u20132000).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results emphasize the improved MSS among men and women in Sweden. The MSS improvements, specifically for the period 2011\u20132020, may be correlated to the introduction of new systemic therapies and are here shown for the first time in detail for Sweden.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad244","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T20:12:48Z","timestamp":1689711168000},"page":"702-709","source":"Crossref","is-referenced-by-count":12,"title":["Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990\u00a0and 2020 in Sweden"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-5472","authenticated-orcid":false,"given":"Sofi","family":"Vikstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Oncology-Pathology"},{"name":"Department of Pathology and Cancer Diagnostics, Radiumhemmet, Karolinska University Hospital Solna , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Mikiver","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine"},{"name":"Regional Cancer Centre Southeast Sweden, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lapins","sequence":"additional","affiliation":[{"name":"Department of Medicine, Unit of Dermatology, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-0455","authenticated-orcid":false,"given":"Kari","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Dermatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden"},{"name":"Department of Dermatology, Sk\u00e5ne University Hospital , Lund , Sweden"},{"name":"Department of Dermatology, Helsingborg Hospital , Helsingborg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismini","family":"Vassilaki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cancer Diagnostics, Radiumhemmet, Karolinska University Hospital Solna , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4988-6346","authenticated-orcid":false,"given":"Johan","family":"Lyth","sequence":"additional","affiliation":[{"name":"Health, Medicine and Caring Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolin","family":"Isaksson","sequence":"additional","affiliation":[{"name":"Surgery, Department of Clinical Sciences, Lund University , Lund , Sweden"},{"name":"Department of Surgery, Kristianstad Hospital , Kristianstad , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Oncology-Pathology"},{"name":"Cancer\u00a0Theme, Unit of Head-Neck-, Lung-, and Skin Cancer, Skin Cancer Centre, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"2024090209465845100_ljad244-B1","author":"International Agency for Research on Cancer and World Health Organization"},{"key":"2024090209465845100_ljad244-B2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024090209465845100_ljad244-B3","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.3390\/cancers13112838","article-title":"Trend shifts in age-specific incidence for in situ and invasive cutaneous melanoma in Sweden","volume":"13","author":"Eriksson","year":"2021","journal-title":"Cancers"},{"key":"2024090209465845100_ljad244-B4","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ejca.2015.07.039","article-title":"Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study","volume":"51","author":"Crocetti","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2024090209465845100_ljad244-B5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"2024090209465845100_ljad244-B6","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2024090209465845100_ljad244-B7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjd.19015","article-title":"Survival in 31 670 patients with thin melanomas: a Swedish population-based study","volume":"184","author":"Isaksson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024090209465845100_ljad244-B8","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/647684","article-title":"Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors","volume":"2012","author":"Tas","year":"2012","journal-title":"J Oncol"},{"key":"2024090209465845100_ljad244-B9","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1002\/cncr.20602","article-title":"Invasive cutaneous malignant melanoma in Sweden, 1990\u20131999","volume":"101","author":"Lindholm","year":"2004","journal-title":"Cancer"},{"key":"2024090209465845100_ljad244-B10","author":"Nationellt kvalitetsregister hudmelanom (SweMR)"},{"key":"2024090209465845100_ljad244-B11","author":"International Agency for Research on Cancer"},{"key":"2024090209465845100_ljad244-B12","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024090209465845100_ljad244-B13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"2024090209465845100_ljad244-B14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"2024090209465845100_ljad244-B15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45269","article-title":"Melanoma treatments and mortality rate trends in the US, 1975 to 2019","volume":"5","author":"Kahlon","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024090209465845100_ljad244-B16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2023.03.019","article-title":"Survival in melanoma in the Nordic countries into the era of targeted and immunological therapies","volume":"186","author":"Tichanek","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"2024090209465845100_ljad244-B17","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/bjd.19010","article-title":"Trends in malignant melanoma mortality in 31 countries from 1985 to 2015","volume":"183","author":"Yang","year":"2020","journal-title":"Br J Dermatol"},{"key":"2024090209465845100_ljad244-B18","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2011.38.0584","article-title":"Superior outcome of women with stage I\/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials","volume":"30","author":"Joosse","year":"2012","journal-title":"J Clin Oncol"},{"key":"2024090209465845100_ljad244-B19","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2012.44.5031","article-title":"Sex is an independent prognostic indicator for survival and relapse\/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European Organisation for Research and Treatment of Cancer randomized controlled trials","volume":"31","author":"Joosse","year":"2013","journal-title":"J Clin Oncol"},{"key":"2024090209465845100_ljad244-B20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bjd.13483","article-title":"Trends in cutaneous malignant melanoma in Sweden 1997\u20132011: thinner tumours and improved survival among men","volume":"172","author":"Lyth","year":"2015","journal-title":"Br J Dermatol"},{"key":"2024090209465845100_ljad244-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canep.2014.10.010","article-title":"Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish population-based register study 1989\u20132011","volume":"39","author":"Bay","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"2024090209465845100_ljad244-B22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjd.12046","article-title":"Incidence and survival in patients with cutaneous malignant melanoma: experience in a U.K. population, 1984\u20132009","volume":"168","author":"Hunter","year":"2013","journal-title":"Br J Dermatol"},{"key":"2024090209465845100_ljad244-B23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2017.12.024","article-title":"Trends in incidence of thick, thin and in situ melanoma in Europe","volume":"92","author":"Sacchetto","year":"2018","journal-title":"Eur J Cancer"},{"key":"2024090209465845100_ljad244-B24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ijc.28956","article-title":"Melanoma incidence trends and survival in adolescents and young adults in Queensland, Australia","volume":"136","author":"Iannacone","year":"2015","journal-title":"Int J Cancer"},{"key":"2024090209465845100_ljad244-B25","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/jdv.12007","article-title":"Melanoma epidemiology, prognosis and trends in Latvia","volume":"27","author":"Azarjana","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024090209465845100_ljad244-B26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjd.21274","article-title":"; CONCORD Working Group. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1\u200a 578 \u200a482 adults diagnosed during 2000\u20132014 in 59 countries (CONCORD-3)","volume":"187","author":"Di Carlo","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024090209465845100_ljad244-B27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jaad.2018.09.018","article-title":"A population-based registry study on relative survival from melanoma in Germany stratified by tumor thickness for each histologic subtype","volume":"80","author":"Brunssen","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024090209465845100_ljad244-B28","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.14129","article-title":"; Eurodermoscopy Working Group. The impact of dermoscopy on melanoma detection in the practice of dermatologists in Europe: results of a pan-European survey","volume":"31","author":"Forsea","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024090209465845100_ljad244-B29","first-page":"669","article-title":"Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting","volume":"159","author":"Vestergaard","year":"2008","journal-title":"Br J Dermatol"},{"key":"2024090209465845100_ljad244-B30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(02)00679-4","article-title":"Diagnostic accuracy of dermoscopy","volume":"3","author":"Kittler","year":"2002","journal-title":"Lancet Oncol"},{"key":"2024090209465845100_ljad244-B31","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/cncr.24162","article-title":"Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia","volume":"115","author":"Geller","year":"2009","journal-title":"Cancer"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad244\/51690947\/ljad244.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/6\/702\/58992251\/ljad244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/6\/702\/58992251\/ljad244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T12:39:32Z","timestamp":1725280772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/6\/702\/7226136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,7,18]]},"published-print":{"date-parts":[[2023,11,16]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad244","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,7,18]]}}}